UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer

PloS one, 2012-09, Vol.7 (9), p.e45357-e45357

2012

Volltextzugriff (PDF)

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Volltextzugriff (PDF)

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4697-4705

2010

Volltextzugriff (PDF)

Metastatic colorectal cancer: recent advances in its clinical management

Expert review of anticancer therapy, 2009-12, Vol.9 (12), p.1829-1847

2009

Volltextzugriff (PDF)

Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC)

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-820-S-821

2011

Volltextzugriff (PDF)

Prognostic factors of long-term outcomes after primary chemo-radiotherapy in non-metastatic anal squamous cell carcinoma: An international bicentric cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15501-e15501

2023

Volltextzugriff (PDF)

Prevalence of KRAS and NRAS mutations in patients with metastatic colorectal cancer in Argentina: A multicenter prospective observational study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15608-e15608

2018

Volltextzugriff (PDF)

Impact of body mass index (BMI) in a breast cancer Argentinian population

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e12622-e12622

2015

Volltextzugriff (PDF)

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data

Biomarkers in medicine, 2017-09, Vol.11 (9), p.751-760

2017

Volltextzugriff (PDF)

Moving foward and beyond the standard through a non-operative management in rectal cancer? Our watch and wait approach experience in Co-Recto

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3561-3561

2015

Volltextzugriff (PDF)

Still Awaiting That Waiting Be a Validated Affordable Option in Rectal Cancer? Our Watch and Wait Approach Experience in Co-Recto

Annals of oncology, 2014-06, Vol.25, p.ii99-ii99

2014

Volltextzugriff (PDF)

Definitive Concurrent Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma. Experience at a Public Hospital in Argentina

Annals of oncology, 2013-06, Vol.24, p.iv54-iv54

2013

Volltextzugriff (PDF)

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3620-3620

2013

Volltextzugriff (PDF)

P-0282 Facing Rectal Cancer Under the Age of 50: Analysis of 140 Patients Discussed in an Multidisciplinary Team (Co-Recto) in Argentina

Annals of oncology, 2012-06, Vol.23, p.iv112

2012

Volltextzugriff (PDF)

Prevención del cáncer colorrectal (CCR)

Acta gastroenterologica latinoamericana, 2005, Vol.35 (2), p.104-140

2005

Volltextzugriff (PDF)

Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.531-531

2012

Volltextzugriff (PDF)

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3511-3511

2013

Volltextzugriff (PDF)

Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)

Annals of oncology, 2013-06, Vol.24, p.iv23-iv24

2013

Volltextzugriff (PDF)

Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study

International journal of radiation oncology, biology, physics, 2002-10, Vol.54 (2), p.397-402

2002

Volltextzugriff (PDF)

El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital

Acta gastroenterologica latinoamericana, 2005, Vol.35 (2), p.94-98

2005

Volltextzugriff (PDF)

Prevention of colorectal cancer

Acta gastroenterologica latinoamericana, 2005, Vol.35 (2), p.104-140

2005

Volltextzugriff (PDF)

Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital

Acta gastroenterologica latinoamericana, 2005, Vol.35 (2), p.94-98

2005

Volltextzugriff (PDF)

Treatment of pain and other symptoms in cancer patients: Patterns in a North American and a South American hospital

Journal of pain and symptom management, 1990, Vol.5 (2), p.78-82

1990

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Englisch
(21)
Spanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(9)
Female
(6)
Male
(6)
Science & Technology
(6)
Adult
(5)
Colorectal Cancer
(5)
Life Sciences & Biomedicine
(5)
Middle Aged
(5)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Colorectal Neoplasms - Mortality
(4)
Colorectal Neoplasms - Pathology
(4)
Mutation
(4)
Oncology
(4)
Biological And Medical Sciences
(3)
Biomarkers
(3)
Colorectal Carcinoma
(3)
Colorectal Neoplasms - Genetics
(3)
Combined Modality Therapy
(3)
Disease-Free Survival
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Metastatic colorectal cancer: recent advances in its clinical management

Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC)

Prognostic factors of long-term outcomes after primary chemo-radiotherapy in non-metastatic anal squamous cell carcinoma: An international bicentric cohort

Prevalence of KRAS and NRAS mutations in patients with metastatic colorectal cancer in Argentina: A multicenter prospective observational study

Impact of body mass index (BMI) in a breast cancer Argentinian population

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data

Moving foward and beyond the standard through a non-operative management in rectal cancer? Our watch and wait approach experience in Co-Recto

Still Awaiting That Waiting Be a Validated Affordable Option in Rectal Cancer? Our Watch and Wait Approach Experience in Co-Recto

Definitive Concurrent Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma. Experience at a Public Hospital in Argentina

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)

P-0282 Facing Rectal Cancer Under the Age of 50: Analysis of 140 Patients Discussed in an Multidisciplinary Team (Co-Recto) in Argentina

Prevención del cáncer colorrectal (CCR)

Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC)

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)

Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study

El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital

Prevention of colorectal cancer

Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital

Treatment of pain and other symptoms in cancer patients: Patterns in a North American and a South American hospital

Suchergebnisse filtern